Navigation Links
Nektar Therapeutics Reports Third Quarter 2011 Financial Results
Date:11/2/2011

p>

(3,388)(4,989)Other assets

(1,750)1Accounts payable

(4,200)1,755Accrued compensation

2,508500Accrued expenses

6,2384,090Accrued clinical trial expenses

1,468(1,408)Deferred revenue

(12,320)(83,107)Other liabilities

(2,681)(2,049)Net cash used in operating activities

$   (71,528)$ (76,278)Cash flows from investing activities:Purchases of investments

(627,529)(315,160)Sales of investments

218,66010,290Maturities of investments

290,810360,906Purchases of property and equipment

(8,294)(22,160)Net cash (used in) provided by investing activities

$ (126,353)$  33,876Cash flows from financing activities:Payments of loan and capital lease obligations

(1,431)(1,119)Issuance of common stock, net of issuance costs

224,0727,142Net cash provided by financing activities

$  222,641$
,023Effect of exchange rates on cash and cash equivalents

493(312)Net increase (decrease) in cash and cash equivalents

$
25,253$ (36,691)Cash and cash equivalents at beginning of period

17,75549,597Cash and cash equivalents at end of period

$
43,008$  12,906
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , Dec. ... SRNE ;  Sorrento), an oncology company developing ... Conkwest, Inc., a privately-held immuno-oncology company developing proprietary ... cell-line based therapy, announced today that the companies ... develop next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies ...
(Date:12/19/2014)... LOS ALTOS, Calif. , Dec. 18, 2014 ... of a new generation of equipment for the ... today the release of the new Luminary™ Profiler, ... highly accurate light-based measurement in a cost-effective, portable ... to meet the specific needs of the cannabis ...
(Date:12/19/2014)... Dec. 18, 2014 Baptist Health Lexington is the ... to receive full Atrial Fibrillation with Electrophysiology Services (EPS) Accreditation ... Atrial fibrillation is the most common cardiac arrhythmia and ... cases can lead to stroke and possible death. More than ... have atrial fibrillation and the numbers are rapidly increasing ...
Breaking Medicine Technology:Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Sage Analytics Develops Breakthrough System for Potency Testing of Cannabis Products 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3
(Date:12/20/2014)... LunaDress has recently announced its 2015 collection of ... on all of its special occasion dresses & wedding apparel. ... wedding gown. If you have no idea of what to ... different wedding dress styles and our dress experts are here ... current special offer, up to 80% off," the CEO of ...
(Date:12/20/2014)... 20, 2014 Recently, VogueQueen.com, a leading ... VogueQueen Big Sale Online for 2015. Great discounts ... new and old consumers can get a discount, up ... the company’s website before January 30, 2015. , VogueQueen.com ... and launched a prom dress promotion. Many customers worldwide ...
(Date:12/20/2014)... Francisco, CA (PRWEB) December 20, 2014 ... Social Innovation company just launched first birthday focused portal ... services, “MERRY BIRTHDAY MESSAGE” launched in both US and ... MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , MERRY ... for everyone’s birthday around the world. , Features, Choose ...
(Date:12/20/2014)... 2014 Xarelto bleeding lawsuits filed ... uncontrollable bleeding and other serious side effects will be ... Louisiana for coordinated pretrial proceedings, Wright & Schulte LLC ... issued an order Friday to transfer 21 Xarelto lawsuits ... federal courts to the Louisiana district court for coordination ...
(Date:12/19/2014)... 20, 2014 Today, Balfleet.com , ... outfits, announces its formal dress promotion. All the old ... to 60% off. , Balfleet.com is well-known for its ... dresses, prom dresses, cocktail dresses and more. Its formal ... money-back guarantee, and they can create an elegant look ...
Breaking Medicine News(10 mins):Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:VogueQueen Big Sale Online For The Coming 2015 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Balfleet.com Announces Its Formal Dress Promotion For 2015 2
... TAMPA, Fla. -- Alexander R. A. Anderson, Ph.D., co-director ... and his colleagues, Simon Hayward, Ph.D., at Vanderbilt University ... have received a five-year, $3 million grant from the ... to predict prostate cancer aggressiveness. "Mathematical models have ...
... HealthDay Reporter , THURSDAY, Oct. 20 (HealthDay News) -- The ... worry about an increased risk of brain cancer, new Danish research ... subject finds no more brain tumors among people who had cell ... phones. Although no one study can rule out harm with ...
... HealthDay Reporter , FRIDAY, Oct. 21 (HealthDay News) ... hormone production as the testes and adrenal glands. But those ... new study, showing hormone production in the penis itself, turn ... in both mice and human tissue, revealing that proteins key ...
... new development paths towards a healthier life. New opportunities ... development, industrial biotechnology and environmental technology have been a ... , VTT is one of the organisers of Metabomeeting ... at the end of September. Professor Jeremy K. Nicholson ...
... scientists advances a strategy for taming the side effects ... medications that work by disrupting the activity of certain ... developed at St. Jude. In this study, scientists showed ... activity of genes in a cell signaling pathway regulated ...
... over the years has made it possible for researchers and ... using ionising radiation, for example X-rays. The images ... of water in the body, since the body is largely ... nuclei in water molecules. It can also be used to ...
Cached Medicine News:Health News:Researchers get $3 million National Institutes of Health grant for mathematical models of prostate cancer aggressiveness 2Health News:Cell Phones Don't Raise Brain Cancer Risk, Study Says 2Health News:Cell Phones Don't Raise Brain Cancer Risk, Study Says 3Health News:Research Suggests Penis Might Produce Testosterone 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 2Health News:Research involving thyroid hormone lays foundation for more targeted drug development 3Health News:New instrument helps researchers see how diseases start and develop in minute detail 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: